Track Diamyd Medical AB (publ) — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Diamyd Medical AB (publ) DMN.F Open Diamyd Medical AB (publ) in new tab

1.53 EUR
EPS
-0.14
P/B
1.05
ROE
-96.32
Beta
2.14
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
EPS-0.14
Book Value1.46
Price to Book1.05
% Insiders31.847%
Growth
Revenue Growth-0.76%

DCF Valuation

Tweak assumptions to recompute fair value for Diamyd Medical AB (publ) (DMN.F)
Currency: EUR
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Diamyd Medical AB (publ) Logo Diamyd Medical AB (publ) Analysis (DMN.F)

Sweden Health Care Official Website Stock

Is Diamyd Medical AB (publ) a good investment? Diamyd Medical AB (publ) (DMN.F) is currently trading at 1.53 EUR.

Investor FAQ

Does Diamyd Medical AB (publ) pay a dividend?

No, it does not currently pay a dividend.

What asset class is Diamyd Medical AB (publ)?

Diamyd Medical AB (publ) is classified as a Stock.

Company Profile

Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was founded in 1984 and is headquartered in Stockholm, Sweden.

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion